Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
332 Results for "
GTP
" in MedChemExpress (MCE) Product Catalog:
Products (332)
332 Results for "GTP" in MCE Product Catalog:
Cat. No.: HY-P790016
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: GBP3; GTP-Binding Protein 3; Guanylate Binding Protein 3; FLJ10961; Guanine Nucleotide-Binding Protein 3; Guanylate-Binding Protein 3 Delta C; Guanylate-Binding Protein 3; GBP-3
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P85846
Synonyms: EFTUD2; KIAA0031; SNRP116; 116 kDa U5 small nuclear ribonucleoprotein component; Elongation factor Tu GTP-binding domain-containing protein 2; SNU114 homolog; hSNU114; U5 snRNP-specific protein; 116 kDa; U5-116 kDa
Cat. No.: HY-145737A
Purity: 99.38%
PROTAC SOS1 degrader-1 TFA is a degrader of SOS1 PROTAC, with a DC50 of 98.4 nM and a Kd value of 44 nM. PROTAC SOS1 degrader-1 TFA induces the formation of a ternary complex with SOS1 and the VCB E3 ubiquitin ligase complex, thereby promoting the ubiquitination and proteasomal degradation of SOS1. PROTAC SOS1 degrader-1 TFA reduces KRAS-GTP levels, inhibits the phosphorylation of ERK in the RAS-RAF-MEK-ERK pathway, and suppresses the proliferation of cancer cells carrying KRAS mutations. PROTAC SOS1 degrader-1 TFA inhibits tumor growth in mouse xenograft models. PROTAC SOS1 degrader-1 TFA can be used for the research of KRAS-driven cancers .
Cat. No.: HY-W013159S
Synonyms: 5′-dGMP-13C10,15N5 disodium
Cat. No.: HY-P87061
Synonyms: AA017882 antibody; AI324259, antibody; Aplysia ras related homolog 9 (RhoC) antibody; Aplysia ras-related homolog 12 antibody; Aplysia RAS-related homolog 6 antibody; Aplysia RAS-related homolog antibody; ARH12 antibody; ARH6 antibody; ARH9 antibody; ARHA antibody; AA017882 antibody; AI324259, antibody; Aplysia ras related homolog 9 (RhoC) antibody; Aplysia ras-related homolog 12 antibody; Aplysia RAS-related homolog 6 antibody; Aplysia RAS-related homolog antibody; ARH12 antibody; ARH6 antibody; ARH9 antibody; ARHA antibody; ARHB antibody; ARHC antibody; H12 antibody; H6 antibody; H9 antibody; MGC117867 antibody; MGC1448 antibody; MGC61427 antibody; MST081 antibody; MSTP081 antibody; Oncogene RHO H12 antibody; Oncogene RHO H6 antibody; Oncogene RHO H9 antibody; OTTHUMP00000013675 antibody; OTTHUMP00000013676 antibody; OTTHUMP00000013802 antibody; OTTHUMP00000013805 antibody; OTTHUMP00000013807 antibody; OTTHUMP00000013809 antibody; OTTMUSP00000025086 antibody; OTTMUSP00000025087 antibody; Ras homolog 9 (RhoC) antibody; Ras homolog gene family, member A antibody; Ras homolog gene family, member B antibody; Ras homolog gene family, member C antibody; RAS-related homolog 9 antibody; Rh -related GTP binding protein RhoC antibody; Rho cDNA clone 12 antibody; rho cDNA clone 6 antibody; rho cDNA clone 9 antibody; Rho related GTP binding protein RhoB antibody; Rho related GTP binding protein RhoC antibody; RHO12 antibody; RHOA antibody; RHOB antibody; RHOC antibody; rhoC GTPase antibody; RHOH12 antibody; RHOH6 antibody; RHOH9 antibody; RP11-426L16.4 antibody; small GTP binding protein RhoA antibody; Small GTP binding protein RhoC antibody; Transforming protein RhoA antibody;
Target:
Research Areas:
MFN2 agonist-1 is an allosteric agonist of mitofusin 2 (MFN2) with an EC50 of 3 nM. MFN2 agonist-1 mimics the MFN2 HR1 peptide to compete for HR2, disrupt the HR1-HR2 autoinhibitory interaction, stabilize the open conformation of MFN2, and promote GTP hydrolysis and mitochondrial fusion. MFN2 agonist-1 acts in a manner dependent on endogenous MFN1 or MFN2, and does not impair cell viability. MFN2 agonist-1 reverses mitochondrial fragmentation, depolarization, aggregation and axonal transport defects, restores bidirectional movement and improves enhanced autophagy. MFN2 agonist-1 is used in studies related to Charcot-Marie-Tooth disease type 2A, Alzheimer's disease, Parkinson's disease and Huntington's disease .
Cat. No.: HY-176785S
Cat. No.: HY-181964
CAS No.: 3023465-19-9
Research Areas:
KRAS G12C-IN-77 is an orally active and selective KRAS G12C covalent dual-state inhibitor that binds with high affinity to both GDP-bound (inactive state) and GTP-bound (active state) KRAS G12C (IC50 = 133 nM). KRAS G12C-IN-77 rapidly inhibits ERK1/2 phosphorylation, induces the formation of covalent adducts with endogenous KRAS G12C, suppresses the expression of MAPK pathway genes, and inhibits the proliferation of KRAS G12C-mutant cells. KRAS G12C-IN-77 is applicable to research related to KRAS G12C-mutant solid tumors, including pancreatic ductal adenocarcinoma and non-small cell lung cancer .
Cat. No.: HY-183246
CAS No.: 2143950-05-2
Target:
Research Areas:
Rac/Cdc42-IN-1, the major phase I metabolite of the oral Rac/Cdc42 inhibitor MBQ-167 (HY-112842) in vivo, is a selective Rac inhibitor. Rac/Cdc42-IN-1 functions by blocking the GTP-binding activation of Rac1, targeting the autophosphorylation of Thr 423/Thr 402/Thr 436 and Ser 141/Ser 144/Ser 154 in downstream PAK1/2/3, with an inhibitory effect superior to that of MBQ-167. Rac/Cdc42-IN-1 significantly inhibits cell migration, and suppresses tumor growth and distant metastasis to the lung, liver and kidney in HER2+ breast cancer mouse models. Rac/Cdc42-IN-1 can be used for targeted research on metastatic breast cancer .
Cat. No.: HY-W013706R
CAS No.: 35908-31-7
Synonyms: ITP trisodium salt (Standard); Inosine triphosphate trisodium salt (Standard)
Cat. No.: HY-P73676
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: RHOA; Ras Homolog Gene Family, Member A; Prev. ARH12; Small GTP Binding Protein RhoA; Prev. ARHA; Rho CDNA Clone 12; Transforming Protein RhoA; Oncogene RHO H12; RHOH12; EDFAOB; Rho12; RHO12; Epididymis Secretory Sperm Binding Protein; H12; Ras Homolog Ge
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P75172
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: GBP1; GTP-Binding Protein 1; Guanylate Binding Protein 1; HuGBP-1; Guanylate-Binding Protein 1; HGBP1; Guanylate Binding Protein 1, Interferon-Inducible, 67kDa; GBP-1; Interferon-Induced Guanylate-Binding Protein 1; Guanylate Binding Protein 1, Interferon
Species:
Human
Source:
HEK293
Cat. No.: HY-P75787
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: GBP2; Guanine Nucleotide-Binding Protein 2; Guanylate Binding Protein 2; GTP-Binding Protein 2; Guanylate-Binding Protein 2; GBP2 Protein; Guanylate Binding Protein 2, Interferon-Inducible; HuGBP-2; Interferon-Induced Guanylate-Binding Protein 2; GBP-2
Species:
Human
Source:
HEK293
Cat. No.: HY-134813R
CAS No.: 2621928-55-8
Target:
Research Areas:
MRTX1133 (Standard) is the analytical standard of MRTX1133 (HY-134813). This product is intended for research and analytical applications. MRTX1133 is a noncovalent, potent, and selective alkyne-based KRAS G12D inhibitor. MRTX1133 optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated KD against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells. MRTX1133 has single digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations .
Cat. No.: HY-144657
CAS No.: 2913176-81-3
Target:
Research Areas:
(4S)-PROTAC SOS1 degrader-1 is a stereoisomer of PROTAC SOS1 degrader-1 (HY-145737). PROTAC SOS1 degrader-1 (Compound 9d) is a degrader of SOS1 PROTAC, with a DC50 of 98.4 nM and a Kd value of 44 nM. PROTAC SOS1 degrader-1 induces the formation of a ternary complex with SOS1 and the VCB E3 ubiquitin ligase complex, thereby promoting the ubiquitination and proteasomal degradation of SOS1. PROTAC SOS1 degrader-1 reduces KRAS-GTP levels, inhibits the phosphorylation of ERK in the RAS-RAF-MEK-ERK pathway, and suppresses the proliferation of cancer cells carrying KRAS mutations. PROTAC SOS1 degrader-1 inhibits tumor growth in mouse xenograft models. PROTAC SOS1 degrader-1 can be used for the research of KRAS-driven cancers .
Cat. No.: HY-144657A
Purity: 98.09%
Target:
Research Areas:
(4S)-PROTAC SOS1 degrader-1 diTFA is a stereoisomer of PROTAC SOS1 degrader-1 (HY-145737). PROTAC SOS1 degrader-1 (Compound 9d) is a degrader of SOS1 PROTAC, with a DC50 of 98.4 nM and a Kd value of 44 nM. PROTAC SOS1 degrader-1 induces the formation of a ternary complex with SOS1 and the VCB E3 ubiquitin ligase complex, thereby promoting the ubiquitination and proteasomal degradation of SOS1. PROTAC SOS1 degrader-1 reduces KRAS-GTP levels, inhibits the phosphorylation of ERK in the RAS-RAF-MEK-ERK pathway, and suppresses the proliferation of cancer cells carrying KRAS mutations. PROTAC SOS1 degrader-1 inhibits tumor growth in mouse xenograft models. PROTAC SOS1 degrader-1 can be used for the research of KRAS-driven cancers .
Cat. No.: HY-175529
KRASG12D-IN-7 is a selective KRAS G12D inhibitor. KRASG12D-IN-7 displays strong binding activity for KRAS G12D in both its GDP- and GTP- bound states, with Kd value of 1.12 nM and 1.86 nM, respectively. KRASG12D-IN-7 inhibits the proliferation of KRAS G12D harboring AsPC-1 cells with an IC50 value of 10 nM and suppresses MAPK signaling. KRASG12D-IN-7 induces G0/G1 phase arrest and apoptosis in AsPC-1 cells, and strongly inhibits their colony formation. KRASG12D-IN-7 can be used for the study of cancers harboring KRAS G12D mutation, particularly pancreatic ductal adenocarcinoma (PDAC) .
Cat. No.: HY-P704241
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: GSPT1; Eukaryotic Peptide Chain Release Factor Subunit 3a; G1 To S Phase Transition 1; G1 To S Phase Transition Protein 1 Homolog; ERF3a; Eukaryotic Release Factor 3a; ETF3A; 551G9.2; GST1; ERF3A; Eukaryotic Peptide Chain Release Factor GTP-Binding Subuni
Species:
Human
Source:
E. coli
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
